| Literature DB >> 32404099 |
Matthew S Harkey1,2, Julie E Davis3, Lori Lyn Price4,5, Robert J Ward6, James W MacKay7, Charles B Eaton8, Grace H Lo9,10, Mary F Barbe11, Ming Zhang12,13, Jincheng Pang14, Alina C Stout15, Bing Lu16, Timothy E McAlindon12, Jeffrey B Driban12.
Abstract
BACKGROUND: We aimed to determine if composite structural measures of knee osteoarthritis (KOA) progression on magnetic resonance (MR) imaging can predict the radiographic onset of accelerated knee osteoarthritis.Entities:
Keywords: Bone marrow lesions; Cartilage; Effusion; Magnetic resonance imaging; Synovitis
Mesh:
Year: 2020 PMID: 32404099 PMCID: PMC7222452 DOI: 10.1186/s12891-020-03338-7
Source DB: PubMed Journal: BMC Musculoskelet Disord ISSN: 1471-2474 Impact factor: 2.362
Fig. 1Examples of Radiographic Changes that Define the Knee Osteoarthritis Groups and the Study Observation Period. This figure provides examples of Kellgren-Lawrence (KL) grades overtime in each of the knee OA groups. We focused on visits up to 2 years prior to and up to 2 years after the index visit
Fig. 2Composite Structural Metrics that Conceptualize Knee Osteoarthritis Progression as the Combination of Cumulative Damage and Disease Activity. Parsimonious semi-automated programs were used to individually assess cartilage damage index, bone marrow lesion volume, and effusion-synovitis. Cumulative damage is the sum of standardized cartilage damage (four regions: medial/lateral tibia/femur). Disease activity is the sum of the standardized volumes of effusion-synovitis (single volumetric measure) and BML (four regions: medial/lateral tibia/femur)
Group Baseline Characteristics
| Knee Osteoarthritis Group | ||||
|---|---|---|---|---|
| Variables | Accelerated | Typical | No | |
| [(means (SD); except where noted) | (n = 125) | (n = 125) | (n = 125) | |
| Females, n(%) | 79 (63%) | 79 (63%) | 79 (63%) | 1.00 |
| Age (years) | 62.5 (8.5)* | 58.4 (8.4) | 57.3 (8.2) | < 0.001 |
| Body mass index (kg/m2) | 29.7 (4.6)* | 28.1 (4.4) | 26.9 (4.4) | < 0.001 |
| Index knee KL Grade = 0, n(%) | 42 (34%)* | 71 (57%)^ | 92 (74%) | < 0.001 |
| WOMAC pain (0–20; ↑score = ↑pain) | 2.6 (3.3) | 1.6 (2.1) | 1.4 (2.0) | 0.08 |
| Overall Global Rating (0–10, ↑score = ↑effect) | 1.7 (1.9)* | 1.1 (1.5) | 0.8 (1.1) | < 0.001 |
| Days with limited activity in prior month | 3.2 (7.3)^ | 1.7 (4.8) | 1.4 (4.3) | 0.03 |
P values are for the overall group main effect from a one-way analysis of variance (for continuous measures) or chi-square tests (for dichotomous variables). * = P < 0.017 versus typical knee osteoarthritis and no knee osteoarthritis, ^ = P < 0.017 versus no knee osteoarthritis
Fig. 3Differences in Composite Structural Metrics in Individuals with Accelerated Compared to Typical and No Knee Osteoarthritis. A. Disease Activity. B. Cumulative Damage. Statistically siginificant differences in accelerated compared to typical(*) or no (^) knee osteoarthritis. Adjusted for sex and factors related to missing magnetic resonance data at the next visit (i.e., age, body mass index, injury, frequent knee pain, days with limited activity in prior month, overall global rating, and WOMAC pain)
Longitudinal Change in Cumulative Damage and Disease Activity From Two to One Year Prior to the Index Visit is Associated with Accelerated Knee Osteoarthritis (AKOA) Development
| Knee Osteoarthritis (KOA) Group | OR (95% Confidence Interval) | ||||
|---|---|---|---|---|---|
| 1-Year Change in Composite Metrics | Accelerated | Typical | No | Accelerated vs Typical KOA (REF) | Accelerated vs No KOA (REF) |
| Cumulative Damage | 0.34 (0.70) | 0.10 (0.44) | 0.01 (0.55) | 1.69 (1.14–2.51)^ | 2.11 (1.41–3.16)^ |
| Disease Activity | 1.49 (3.20) | 0.61 (1.72) | 0.06 (1.52) | 1.58 (1.08–2.33)^ | 2.39 (1.55–3.71)^ |
OR odds ratio,
Adjusted for age, BMI, sex, race, WOMAC pain, KL grade, and pain medication at the visit 2 years prior to the index visit
Odds ratios are reported as increased odds for developing accelerated knee osteoarthritis per entire group standard deviation for one-year change in cumulative damage (i.e., 0.60) and disease activity (i.e., 2.37)
^Statistically significant (p< 0.05)